Volume 1, Issue 3 (12-2015)                   IrJNS 2015, 1(3): 16-20 | Back to browse issues page

XML Print

Abstract:   (1826 Views)

Background & Aim: Glioblastoma multiforme (GBM), the highest grade glioma (grade IV), is the most malignant form of astrocytoma in adults. This study aimed at evaluating the relationship between demographic, clinical and medical factors with GBM outcome.

Methods & Materials/Patients: Through a cross-sectional design, 58 patients with newly diagnosed GBM were studied from 1999 to 2015 in Guilan province (North of Iran). Demographic, clinical and medical data including age, gender, score of Karnofsky Performance Scale (KPS), status at discharge, extent of resection (EOR) and administration of post-operative radio-chemotherapy were recorded in an individual questionnaire. The data were analyzed using chi-square and fisher exact tests. Results: Of all patients, 35 (60.3%) cases were men and 23 (39.7%) were women. Age range (at the time of diagnosis of GBM) was 18-82 years (54.86±16.34). The most common side and location of tumor were left hemisphere and frontal lobe, respectively. 41 patients (70.7%) received total surgical resection. Half of patients were treated with simultaneous post-operative radiation therapy and chemotherapy.11 (19%) of all cases died. About 41 (70.6%) of patients demonstrated KPS 50-70.

Conclusion: GBM is a frequent malignant brain tumor with male predominance and high occurrence in age range of ≥50 years. The number of dead patients increases with decreased KPS. Total surgical resection followed by concomitant radiation therapy and chemotherapy were common standard therapeutic regimens.

Full Text [PDF 360 kb]   (700 Downloads) |   |   Full Text (HTML)  (79 Views)  
Type of Study: Research | Subject: Gamma Knife Radiosurgery
* Corresponding Author Address: *Corresponding Author Address: Guilan Road Trauma Research Center, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Guilan, Iran. Tel: +981333368773, Fax: +981333339842. E-mail: haghdoostzahra@yahoo.com

1. American Brain Tumor Association. Glioblastoma and Malignant Astrocytoma, Medical Center, Los Angeles, California.pdf.
2. Dobes M, Khurana VG, Shadbolt B, Jain S, Smith SF, Smee R, et al. Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of Schwannoma (2000–2008): findings of a multicenter Australian study. Surgical neurology international. 2011; 2:176. doi: 10.4103/2152-7806.90696. [DOI:10.4103/2152-7806.90696]
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005; 352(10): 987-96. [DOI:10.1056/NEJMoa043330] [PMID]
4. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta neuropathologica. 2007; 114(2): 97-109. [DOI:10.1007/s00401-007-0243-4] [PMID] [PMCID]
5. CBTRUS: Statistical report: primary brain tumors in the United States, 2000-2004. Central brain tumor registry of the United States, Chicago, 2008.
6. Jazayeri SB, Rahimi-Movaghar V, Shokraneh F , Saadat S , Ramezani R. Epidemiology of Primary CNS Tumours in Iran: A Systematic Review. Asian Pacific Journal of Cancer Prevention. 2013; 14 (6): 3979-3985. [DOI:10.7314/APJCP.2013.14.6.3979] [PMID]
7. Dubrow R, Darefsky AS. Demographic variation in incidence of adult glioma by subtype, United States, 1992–2007. BioMed Central cancer. 2011; 11:325. doi: 10.1186/1471-2407-11-325. [DOI:10.1186/1471-2407-11-325]
8. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, et al. Long-term survival with glioblastoma multiforme. Brain : a journal of neurology. 2007; 130: 2596–2606. [DOI:10.1093/brain/awm204] [PMID]
9. Deb P, Sharma MC, Mahapatra AK, Agarwal D, Sarkar C. Glioblastoma multiforme with long term survival. Neurology India. 2005; 53(3): 329–332. [DOI:10.4103/0028-3886.16934] [PMID]
10. Ewelt C, Goeppert M, Rapp M, Steiger HJ, Stummer W, Sabel M. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival. Journal of neuro-oncology. 2011; 103(3): 611-8. doi: 10.1007/s11060-010-0429-9. [DOI:10.1007/s11060-010-0429-9]
11. Clarke J, Butowski N, Chang SR. Recent advances in therapy for glioblastoma. Archives of neurology. 2010; 67(3): 279-283. [DOI:10.1001/archneurol.2010.5] [PMID]
12. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005; 23(10): 2372-7. [DOI:10.1200/JCO.2005.00.331] [PMID]
13. Julka PK, Sharma DN, Mallick S, Gandhi AK, Joshi N, Rath GK. Postoperative treatment of glioblastoma multiforme with radiation therapy plus concomitant and adjuvant temozolomide : A mono-institutional experience of 215 patients. Journal of cancer research and therapeutics . 2013; 9(3): 381-386. [DOI:10.4103/0973-1482.119310] [PMID]
14. Chambless LB, Kistka HM, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC. The relative value of postoperative versus preoperative Karnofsky Performance Scale scores as a predictor of survival after surgical resection of glioblastoma multiforme. Journal of Neurooncology. 2015; 121(2): 359-64. [DOI:10.1007/s11060-014-1640-x] [PMID]
15. Ekici MA, Bulut T, Tucer B, Basarslan SK, Kurtsoy A. Prognostic factors in patients with glioblastoma multiforme (clinical research). Turkish Journal of Medical Sciences. 2013; 43: 795-804. doi:10.3906/sag-1204-45 [DOI:10.3906/sag-1204-45]
16. Currow DC, Fallon M, Cherny NI, Portenoy RK, Kaasa S. Oxford Textbook of Palliative Medicine. Oxford University Press, 5th Ed, 2015.
17. Kumar N, Kumar P, Angurana SL, Khosla D, Mukherjee KK, Aggarwal R, et al. Evaluation of outcome and prognostic factors in patients of glioblastoma multiforme: A single institution experience. Journal of Neurosciences Rural Practice. 2013; 4(Suppl 1): S46–S55. doi: 10.4103/0976-3147.116455. [DOI:10.4103/0976-3147.116455]
18. Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: Data from the glioma outcomes project. Journal of Neurosurgery. 2003; 99 (3): 467–73. [DOI:10.3171/jns.2003.99.3.0467] [PMID]
19. Matsuda M, Yamamoto T, Ishikawa E, Nakai K, Zaboronok A, Takano S, et al. Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy. The British Journal of Radiology. 2011; 84 (Spec Iss 1): S54–S60. DOI: 10.1259/bjr/29022270. [DOI:10.1259/bjr/29022270]
20. Brandes AA, Monfardini S. The treatment of elderly patients with high-grade gliomas. Seminars in Oncology. 2003; 30(6 Suppl 19): 77–80. [DOI:10.1053/j.seminoncol.2003.11.025]
21. Gundersen S, Lote K, Hannisdal E. Prognostic factors for glioblastoma multiforme-development of a prognostic index. Acta Oncol. 1996; 35: 123–7. [DOI:10.3109/02841869609098530] [PMID]
22. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. The Lancet. Oncology. 2008; 9(1): 29–38. [DOI:10.1016/S1470-2045(07)70384-4]
23. Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma Trials. J Natl Cancer Inst. 1993; 85: 704–10. [DOI:10.1093/jnci/85.9.704] [PMID]
24. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection and survival. Journal of neurosurgery. 2001; 95(2): 190–8. [DOI:10.3171/jns.2001.95.2.0190] [PMID]
25. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of cancer. Cancer. 1948; 1(4): 634-656. https://doi.org/10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L [DOI:10.1002/1097-0142(194811)1:43.0.CO;2-L]
26. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of Chemotherapeutic Agents. New York: Columbia University Press, 1949, I9 1-205.
27. Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale An Examination of its Reliability and Validity in a Research Setting. Cancer. 1984; 53(9): 2002-2007. https://doi.org/10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W [DOI:10.1002/1097-0142(19840501)53:93.0.CO;2-W]
28. Carlsson SK, Brothers SP, Wahlestedt C. Emerging treatment strategies for glioblastoma multiforme. EMBO Molecular Medicine . 2014; 6(11): 1359–1370. [DOI:10.15252/emmm.201302627] [PMID] [PMCID]
29. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008; 62(4): 753–766. [DOI:10.1227/01.neu.0000318159.21731.cf] [PMID]
30. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. Journal of neurosurgery. 2011; 115(1): 3–8. [DOI:10.3171/2011.2.JNS10998] [PMID]
31. Margusian R. Survival analysis in patients whit Glioblastoma Multiforme. AMA, 10th edition; 2011.
32. Orringer D, Lau D, Khatri S, Zamora-Berridi GJ, Zhang K, Wu C, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. Journal of neurosurgery. 2012; 117(5): 851 – 859. [DOI:10.3171/2012.8.JNS12234] [PMID]
33. Mineo JF , Bordron A, Baroncini M, Ramirez C, Maurage CA, Blond S, et al. Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta neurochirurgica. 2007; 149(3): 245–253. [DOI:10.1007/s00701-006-1092-y] [PMID]
34. Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone MG, Caldiroli D, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro-Oncology. 2008; 10(1): 79–87. [DOI:10.1215/15228517-2007-038] [PMID] [PMCID]
35. Tanaka S, Meyer FB, Buckner JC, Uhm JH, Yan ES, Parney IF. Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients. Journal of Neurosurgery. 2013; 118(4): 786–98. [DOI:10.3171/2012.10.JNS112268] [PMID]
36. Yount GL, Haas-Kogan DA, Vidair CA, Haas M, Dewey WC, Israel MA. Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells. Cancer research. 1996; 56(3): 500–6. [PMID]
37. Haas-Kogan DA, Yount G, Haas M, Levi D, Kogan SS, Hu L, et al. p53-dependent G1 arrest and p53-independent apoptosis influence radiobiologic response of glioblastoma. International journal of radiation oncology, biology, physics. 1996; 36(1): 95–103. [DOI:10.1016/S0360-3016(96)00244-1]
38. Louis DN. The p53 gene and protein in human brain tumors. Journal of neuropathology and experimental neurology. 1994; 53(1): 11–21. [DOI:10.1097/00005072-199401000-00002] [PMID]
39. Leenstra S, Bijlsma EK, Troost D, Oosting J, Westerveld A, Bosch DA, et al. Allele loss on chromosomes 10 and 17p and epidermal growth factor receptor gene amplification in human malignant astrocytoma related to prognosis. British journal of cancer. 1994; 70(4): 684–9. [DOI:10.1038/bjc.1994.373] [PMID] [PMCID]
40. Wang Y, Li S, Zhang Z, Chen X, You G, Yang P, et al. Surgical extent impacts the value of the established prognosticators in glioblastoma patients: a prospective translational study in Asia. Head and Neck Oncology. 2012; 4: 80.
41. Stupp R, Mason WP, van den Bent BM, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005; 352: 987 – 996. [DOI:10.1056/NEJMoa043330] [PMID]
42. Barker CA, Chang M, Chou JF, Zhang Z, Beal K, Gutin PH, et al. Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. Journal of Neurooncology. 2012; 109(2): 391-7. [DOI:10.1007/s11060-012-0906-4] [PMID] [PMCID]